Adding two blood-borne proteins associated with cancer cell migration increases the predictive ability of the current biomarker for pancreatic cancer to detect early-stage disease, an MD Anderson research team reports in the Journal of the National Cancer Institute.
The trio of biomarkers, tested in three separate cohorts, including two blinded validation studies, improved the detection of patients with early-stage disease...
A new trial underway at MD Anderson may lead to new therapies for triple negative breast cancer.
Fifteen to 20% of breast cancers...
Immunotherapy is complex, has curative potential for some patients when given alone or combined with other drugs, and needs further support...